Difference between revisions of "Edrecolomab (Panorex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Discontinued" to "Category:Discontinued drugs") |
m |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| + | ''This medication was never approved by the FDA, but was the first monoclonal antibody approved for a cancer indication, in Germany (1995).'' | ||
| + | |||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/edrecolomab NCI Drug Dictionary]: A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/edrecolomab NCI Drug Dictionary]: A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. | ||
| Line 7: | Line 9: | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Panorex | *'''Brand name:''' Panorex | ||
| − | |||
| − | |||
| − | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Anti-EpCAM antibodies]] | [[Category:Anti-EpCAM antibodies]] | ||
| − | [[Category:EMA approved | + | [[Category:Colon cancer medications (historic)]] |
| + | |||
| + | [[Category:EMA approved in 1995]] | ||
[[Category:Discontinued drugs]] | [[Category:Discontinued drugs]] | ||
Latest revision as of 12:17, 11 June 2023
This medication was never approved by the FDA, but was the first monoclonal antibody approved for a cancer indication, in Germany (1995).
Mechanism of action
From the NCI Drug Dictionary: A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity.
Diseases for which it was used
Also known as
- Brand name: Panorex